FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1989071330> ?p ?o ?g. }

• W1989071330 endingPage "62" @default.
• W1989071330 startingPage "60" @default.
• W1989071330 abstract "Late diabetes is characterized by accelerated arteriosclerosis, increased incidence of myocardial infarction, and excessive fibrin deposition in the microcirculation. It is believed that drugs which enhance endogenous fibrinolysis might retard or even reverse these complications. Gliclazide, a second generation sulphonylurea, has previously been reported to increase the protein concentration of t-PA in diabetic patients. Presently, we have in type 1 diabetic patients studied the effect of gliclazide on inhibition and activation of u-PA. Twenty-three non-obese male type 1 diabetics without residual ,β-cell function were included in the study. The patients received gliclazide for a period of 6 months either in a dose of 160 mg/day (n = 11) or in a dose of 240 mg/day (n = 12). Blood samples were collected immediately before, after 3 months and after 6 months of treatment, and finally 1 month after treatment had been stopped. The protein concentrations of u-PA, PAI-1 and PAP-complexes were determined by ELISA methods. Activatable scu-PA was determined by a Bio-Immune-Assay. Friedman's X2 test was used for statistical analysis. When all patients were combined we observed that the concentration of PAI-1 antigen decreased significantly (p < 0.02) during treatment while PAP-complexes remained stable. When the two groups of patients were separated we observed that the concentrations of both u-PA (p < 0.01) and activatable scu-PA (p < 0.01) decreased significantly in patients treated with 160 mg of gliclazide while the concentrations of all the variables studied remained unchanged in patients receiving 240 mg. Insulin demand, metabolic variables, and weight remained stable during the study period. The results from the present exploratory study suggest that gliclazide has the capability to affect activatable scu-PA, u-PA, and PAI-1 in a subset of type 1 diabetic patients. Since effective fibrinolysis (PAP-complexes) remains unchanged these observations might indicate an effect on endothelial cell function." @default.
• W1989071330 created "2016-06-24" @default.
• W1989071330 creator A5021188751 @default.
• W1989071330 creator A5025976955 @default.
• W1989071330 creator A5037914796 @default.
• W1989071330 creator A5072577339 @default.
• W1989071330 date "1994-01-01" @default.
• W1989071330 modified "2023-09-26" @default.
• W1989071330 title "The effect of gliclazide on plasma urokinase-related fibrinolysis. The results from an exploratory study" @default.
• W1989071330 cites W1988062262 @default.
• W1989071330 cites W2062330496 @default.
• W1989071330 cites W2071046019 @default.
• W1989071330 cites W2084784103 @default.
• W1989071330 cites W2418420996 @default.
• W1989071330 doi "https://doi.org/10.1016/0268-9499(94)90247-x" @default.
• W1989071330 hasPublicationYear "1994" @default.
• W1989071330 type Work @default.
• W1989071330 sameAs 1989071330 @default.
• W1989071330 citedByCount "1" @default.
• W1989071330 crossrefType "journal-article" @default.
• W1989071330 hasAuthorship W1989071330A5021188751 @default.
• W1989071330 hasAuthorship W1989071330A5025976955 @default.
• W1989071330 hasAuthorship W1989071330A5037914796 @default.
• W1989071330 hasAuthorship W1989071330A5072577339 @default.
• W1989071330 hasConcept C126322002 @default.
• W1989071330 hasConcept C134018914 @default.
• W1989071330 hasConcept C2776393769 @default.
• W1989071330 hasConcept C2776825266 @default.
• W1989071330 hasConcept C2777448766 @default.
• W1989071330 hasConcept C2779679481 @default.
• W1989071330 hasConcept C500558357 @default.
• W1989071330 hasConcept C555293320 @default.
• W1989071330 hasConcept C71924100 @default.
• W1989071330 hasConcept C90924648 @default.
• W1989071330 hasConceptScore W1989071330C126322002 @default.
• W1989071330 hasConceptScore W1989071330C134018914 @default.
• W1989071330 hasConceptScore W1989071330C2776393769 @default.
• W1989071330 hasConceptScore W1989071330C2776825266 @default.
• W1989071330 hasConceptScore W1989071330C2777448766 @default.
• W1989071330 hasConceptScore W1989071330C2779679481 @default.
• W1989071330 hasConceptScore W1989071330C500558357 @default.
• W1989071330 hasConceptScore W1989071330C555293320 @default.
• W1989071330 hasConceptScore W1989071330C71924100 @default.
• W1989071330 hasConceptScore W1989071330C90924648 @default.
• W1989071330 hasLocation W19890713301 @default.
• W1989071330 hasOpenAccess W1989071330 @default.
• W1989071330 hasPrimaryLocation W19890713301 @default.
• W1989071330 hasRelatedWork W1781372697 @default.
• W1989071330 hasRelatedWork W1989071330 @default.
• W1989071330 hasRelatedWork W1995024643 @default.
• W1989071330 hasRelatedWork W2033324666 @default.
• W1989071330 hasRelatedWork W2044021074 @default.
• W1989071330 hasRelatedWork W2139801262 @default.
• W1989071330 hasRelatedWork W2143676904 @default.
• W1989071330 hasRelatedWork W2152355615 @default.
• W1989071330 hasRelatedWork W4237250711 @default.
• W1989071330 hasRelatedWork W2050310915 @default.
• W1989071330 hasVolume "8" @default.
• W1989071330 isParatext "false" @default.
• W1989071330 isRetracted "false" @default.
• W1989071330 magId "1989071330" @default.
• W1989071330 workType "article" @default.